CRIS Current Research Information System

SIMONETTI, GIORGIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.125
EU - Europa 3.387
AS - Asia 1.757
AF - Africa 271
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 8
SA - Sud America 7
Totale 9.564
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.102
GB - Regno Unito 1.072
VN - Vietnam 976
SE - Svezia 555
IT - Italia 547
CN - Cina 472
DE - Germania 423
IN - India 171
IE - Irlanda 157
FR - Francia 144
RU - Federazione Russa 99
TG - Togo 95
ZA - Sudafrica 79
EE - Estonia 77
UA - Ucraina 77
BG - Bulgaria 71
CH - Svizzera 48
CI - Costa d'Avorio 48
NG - Nigeria 46
BE - Belgio 42
JO - Giordania 41
FI - Finlandia 27
SG - Singapore 23
CA - Canada 22
IR - Iran 16
UZ - Uzbekistan 14
GR - Grecia 12
NL - Olanda 10
EU - Europa 9
HK - Hong Kong 9
JP - Giappone 9
AU - Australia 6
LB - Libano 6
ES - Italia 5
AT - Austria 4
ID - Indonesia 4
KR - Corea 4
BR - Brasile 3
HR - Croazia 3
MK - Macedonia 3
PL - Polonia 3
TR - Turchia 3
CL - Cile 2
HU - Ungheria 2
NZ - Nuova Zelanda 2
PE - Perù 2
PT - Portogallo 2
RO - Romania 2
SC - Seychelles 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
EG - Egitto 1
HN - Honduras 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MY - Malesia 1
SA - Arabia Saudita 1
Totale 9.564
Salva come PNG Salva come JPEG
Città #
Southend 994
Dong Ket 772
Chandler 541
Fairfield 458
Ashburn 323
Ann Arbor 305
Houston 278
Woodbridge 234
Wilmington 230
Seattle 216
Cambridge 183
Princeton 170
Dublin 156
Bologna 130
Beijing 100
Lomé 95
Westminster 83
Padova 79
Nanjing 77
Sofia 68
New York 66
Medford 60
Berlin 49
Abidjan 48
Boardman 47
Abeokuta 46
Amman 41
Brussels 41
Bern 39
Jinan 37
Bremen 36
Milan 36
Redwood City 33
Shenyang 33
Saint Petersburg 32
Changsha 30
Hebei 30
Nanchang 29
Helsinki 26
Turin 26
Falls Church 25
Jiaxing 23
San Diego 23
Florence 19
Jacksonville 19
Paris 18
Mountain View 17
Redmond 14
Singapore 14
Haikou 13
Hangzhou 13
Toronto 13
Dearborn 12
Ningbo 11
Guangzhou 9
Los Angeles 9
Norwalk 9
Taizhou 9
Lanzhou 8
Leawood 8
Romainville 8
Tianjin 7
Tokyo 7
Forlì 6
Fremont 6
Hong Kong 6
London 6
Monmouth Junction 6
Olalla 6
San Francisco 6
Zhengzhou 6
Amsterdam 5
Athens 5
Augusta 5
Muizenberg 5
Napoli 5
Phoenix 5
Pune 5
Rome 5
Bühl 4
Jakarta 4
Kilburn 4
Kuban 4
Kunming 4
Mülheim 4
Reggio Emilia 4
Taiyuan 4
Vienna 4
Zanjan 4
Andover 3
Bitola 3
Boydton 3
Busseto 3
Camden 3
Castellammare del Golfo 3
Central 3
Chengdu 3
Chicago 3
Ferrara 3
Frankfurt Am Main 3
Totale 6.746
Salva come PNG Salva come JPEG
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 268
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 228
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 221
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 205
5′UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia 188
Acute myeloid leukemia cell and stem-progenitor cell behavior studied in mimetic bone marrow microenvironment 187
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 185
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 181
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 180
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 177
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 173
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 167
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 165
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 160
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 150
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 147
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis 146
Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations 139
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 133
Network integration of multi-tumour omics data suggests novel targeting strategies 133
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 133
A novel Rag2-/- c-/--xenograft model of human CLL 129
Clec12a: A new AML stem cell-associated antigen 128
Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data 128
null 123
Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 122
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 122
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 121
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 120
Fanconi anemia gene variants in therapy-related myeloid neoplasms 118
Transcriptional Regulation of Germinal Center B and Plasma Cell Fates by Dynamical Control of IRF4 117
An analysis pipeline for variant discovery in Whole Exome Sequencing data of cancer samples. 116
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 116
HS1 has a central role in the trafficking and homing of leukemic B cells 113
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 113
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 112
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 111
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 111
Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression 109
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 109
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 109
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 109
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 107
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 105
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 104
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 103
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 103
SNP array reveals a new deletion of JAK2 in AML patients 103
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 100
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 99
Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels 98
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 96
Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells 96
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 95
Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models 92
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 92
The role of Toll-like receptors in chronic B cell malignancies 90
Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions 89
SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders 84
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination 84
Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia 84
Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia 83
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 83
The diverse roles of IRF4 in late germinal center B-cell differentiation 82
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 82
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 82
Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia 80
Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy 79
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 79
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 79
IRF4 controls the positioning of mature B cells in the lymphoid microenvironments by regulating NOTCH2 expression and activity 79
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 77
Gene expression signature of aneuploidy in acute myeloid leukemia 76
Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients 75
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 75
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 74
Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia 73
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 71
Germinal center B cell maintenance and differentiation are controlled by distinct NF- B transcription factor subunits 67
Novel Mouse Models of Chronic Lymphocytic Leukemia (CLL) Unravel the Molecular Mechanisms Controlling Bone Marrow Involvement by Leukemic B Cells 66
The Irf4 Gene, a Susceptibility Locus for Chronic Lymphocytic Leukemia (CLL), Controls Establishment of Follicular and Marginal Zone B Cell Compartments in Mice 62
Differential Expression and Non-Redundant Functions of NF-kappa B Transcription Factor Subunits in Germinal Center (GC) B Cell Subpopulations 56
Hemiaminals from amino-azaheterocycles and chloral hydrate as synthons for the access to novel compounds with potential biological activity 52
Synthon-approach starting from amino-azaheterocycles to obtain new compounds with potential antiproliferative activity 49
Release of IFNg by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells 42
Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells 34
CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies 32
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 28
P-206 3D in vitro modelling of relapsed/refractory multiple myeloma to unveil mechanisms of acquired resistance to therapy 20
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin 17
The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells 17
Potential CDC20 inhibitors: synthesis and biological evaluation of Apcin analogues 16
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 16
Impact on the Transcriptome of Proton Beam Irradiation Targeted at Healthy Cardiac Tissue of Mice 6
The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials 1
Totale 9.856
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.821
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.821
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.303 334 75 7 128 249 206 280 291 328 185 114 106
2020/20211.916 214 72 38 42 53 78 44 105 146 65 93 966
2021/20221.892 253 55 109 185 191 94 46 101 84 101 351 322
2022/20232.182 238 310 122 301 176 178 58 109 365 57 167 101
2023/2024654 22 99 32 84 41 159 38 57 32 39 22 29
2024/20256 6 0 0 0 0 0 0 0 0 0 0 0
Totale 9.856